Abstract：
Acquired brain injury (ABI), such as traumatic brain injury and stroke, is a leading cause of disability worldwide, resulting in debilitating acute and chronic symptoms, as well as an increased risk of developing neurological and neurodegenerative disorders. These symptoms can stem from various neurophysiological insults, including neuroinflammation, oxidative stress, imbalances in neurotransmission, and impaired neuroplasticity. Despite advancements in medical technology and treatment interventions, managing ABI remains a significant challenge. Emerging evidence suggests that psychedelics may rapidly improve neurobehavioral outcomes in patients with various disorders that share physiological similarities with ABI. However, research specifically focussed on psychedelics for ABI is limited. This narrative literature review explores the neurochemical properties of psychedelics as a therapeutic intervention for ABI, with a focus on serotonin receptors, sigma-1 receptors, and neurotrophic signalling associated with neuroprotection, neuroplasticity, and neuroinflammation. The promotion of neuronal growth, cell survival, and anti-inflammatory properties exhibited by psychedelics strongly supports their potential benefit in managing ABI. Further research and translational efforts are required to elucidate their therapeutic mechanisms of action and to evaluate their effectiveness in treating the acute and chronic phases of ABI.
摘要：
获得性脑损伤（ABI），比如创伤性脑损伤和中风，是全球残疾的主要原因，导致急性和慢性症状，以及增加患神经和神经退行性疾病的风险。这些症状可能源于各种神经生理损伤，包括神经炎症,氧化应激，神经传递失衡，神经可塑性受损.尽管医疗技术和治疗干预措施取得了进步，管理ABI仍然是一个重大挑战。新出现的证据表明，迷幻药可以迅速改善患有与ABI具有生理相似性的各种疾病的患者的神经行为结果。然而,专门针对ABI迷幻药的研究有限。这篇叙述性文献综述探讨了迷幻药作为ABI治疗干预的神经化学特性，专注于血清素受体，sigma-1受体，与神经保护相关的神经营养信号，神经可塑性，和神经炎症。促进神经元生长，细胞存活,迷幻药所表现出的抗炎特性强烈支持其在管理ABI方面的潜在益处。需要进一步的研究和转化努力来阐明其治疗作用机制并评估其治疗ABI急性和慢性期的有效性。
